Australian Patent Granted for Norwood Immunology

Norwood Abbey announced that a further patent relating to its immunology technology has been granted in Australia, further strengthening Norwood's intellectual property position in the immunology area. Norwood's immunology technology is based on the use of U.S. Food and Drug Administration (FDA)-approved GnRH analogue drugs to regenerate the thymus gland and enhance bone marrow function. This "re-boots" the body's immune system so it can produce new T cells, enabling patients to better respond to disease.